The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. (2018)

First Author: Herrington WG

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/ckj/sfy090

PubMed Identifier: 30524708

Publication URI: http://europepmc.org/abstract/MED/30524708

Type: Journal Article/Review

Volume: 11

Parent Publication: Clinical kidney journal

Issue: 6

ISSN: 2048-8505